Table 1 Baseline characteristics of the 5260 breast cancer patients receiving radiotherapy between 2005 and 2016, stratified for boost and without boost
Characteristic | Total | Radiotherapy | |
|---|---|---|---|
With boost | Without boost | ||
N (%) | 5260 | 1917 (36.4) | 3343 (63.6) |
Follow-up time, mean (SD), months | 80.3 (37.1) | 111.6 (32.8) | 62.4 (25.8) |
Age at diagnosis, mean (SD) | 57.8 (10.7) | 54.0 (8.8) | 60.0 (11.0) |
BMI, mean (SD) | 27.1 (2.7) | 27.1 (2.7) | 27.5 (2.6) |
Menopausal status, N (%) | |||
Premenopausal | 1231 (23.4) | 141 (7.4) | 1090 (32.6) |
Perimenopausal | 262 (5.0) | 138 (7.2) | 124 (3.7) |
Postmenopausal | 3767 (71.6) | 1638 (85.4) | 2129 (63.7) |
Laterality, N (%) | |||
Left-sided | 2710 (51.5) | 977 (51.0) | 1733 (51.8) |
Tumor stage, N (%) | |||
DCIS/T0 | 733 (13.9) | 251 (13.1) | 482 (14.4) |
T1 | 3232 (61.4) | 1237 (64.5) | 1995 (59.7) |
T2 | 1077 (20.5) | 410 (21.4) | 667 (20.0) |
T3+ | 125 (2.4) | < 10 a | < 10 a |
Unknown | 93 (1.8) | < 10 a | < 10 a |
Lymph nodes, N (%) | |||
Negative | 3733 (71.0) | 1402 (73.1) | 2331 (69.7) |
Positive | 1415 (26.9) | 501 (26.1) | 914 (27.3) |
Unknown | 112 (2.1) | 14 (0.7) | 98 (2.9) |
Differentiation grade, N (%) | |||
Well differentiated | 1468 (27.9) | 580 (30.3) | 888 (26.6) |
Moderately differentiated | 1888 (35.9) | 649 (33.9) | 1239 (37.1) |
Poorly differentiated | 1388 (26.4) | 536 (28.0) | 852 (25.5) |
Unknown / not reported | 516 (9.8) | 152 (7.9) | 364 (10.9) |
Receptor status, N (%) b | |||
ER positive | 4180 (79.5) | 1645 (85.8) | 2535 (75.8) |
PR positive | 3816 (72.5) | 1642 (85.7) | 2174 (65.0) |
HER2 positive | 1112 (21.1) | 391 (20.4) | 721 (21.6) |
Triple negative | 716 (13.6) | 265 (13.8) | 451 (13.5) |
Surgery, N (%) | |||
Lumpectomy | 4787 (91.0) | 1899 (99.1) | 2888 (86.4) |
Mastectomy | 459 (8.7) | 16 (0.8) | 443 (13.3) |
Unknown | 14 (0.3) | 2 (0.1) | 12 (0.3) |
Chemotherapy, N (%) | |||
With anthracyclines | 1253 (23.8) | 191 (10.0) | 1062 (31.8) |
Without anthracyclines | 758 (14.4) | 589 (30.7) | 169 (5.1) |
None / Unknown | 3249 (61.8) | 1137 (59.3) | 2112 (63.2) |
Targeted therapy, N (%) | |||
Trastuzumab | 367 (7.0) | 121 (6.3) | 246 (7.4) |
None / Unknown | 4893 (93.0) | 1796 (93.7) | 3097 (92.6) |
Endocrine therapy, N (%) | |||
Aromatase inhibitors | 113 (2.1) | 32 (1.7) | 81 (2.4) |
Tamoxifen c | 1402 (26.7) | 171 (8.9) | 1231 (36.8) |
Type of hormone therapy unknown | 727 (13.8) | 520 (27.1) | 207 (6.2) |
None / Unknown | 3018 (57.4) | 1194 (62.3) | 1824 (54.6) |
CAC score in Agatston units, N (%) | |||
0 | 3795 (72.1) | 1404 (73.2) | 2391 (71.5) |
1–10 | 583 (11.1) | 241 (12.6) | 342 (10.2) |
11–100 | 593 (11.3) | 204 (10.6) | 389 (11.6) |
101–400 | 208 (4.0) | 49 (2.6) | 159 (4.8) |
> 400 | 81 (1.5) | 19 (1.0) | 62 (1.9) |
TAC in Agatston units, N (%) | |||
0 | 1845 (35.1) | 717 (37.4) | 1128 (33.7) |
≥ 1 | 3415 (64.9) | 1200 (62.6) | 2215 (66.3) |